048530.KQ
iNtRON Biotechnology, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 2,810.00
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.2B | 5.7B | 6.4B | 9.6B | 14.0B |
| Cost of Revenue | 4.8B | 3.6B | 2.7B | 5.0B | 5.6B |
| Gross Profit | 2.5B | 2.2B | 3.7B | 4.6B | 8.5B |
| Operating Expenses | |||||
| R&D Expense | 4.4B | 4.7B | 3.5B | 3.2B | 3.3B |
| SG&A Expense | 2.9B | 1.7B | 1.5B | 4.9B | 6.8B |
| General & Admin Expense | 961.2M | 1.0B | 953.5M | 1.2B | 1.0B |
| Selling & Marketing Expense | 619.8M | 630.4M | 539.9M | 1.1B | 922.5M |
| Other Expenses | 3.2B | 3.7B | 4.0B | (274.0M) | — |
| Total Operating Expenses | 10.4B | 10.1B | 9.0B | 7.8B | 10.1B |
| Cost and Expenses | 15.2B | 13.6B | 11.7B | 12.9B | 15.5B |
| Operating Income (EBIT) | (7.9B) | (7.9B) | (5.2B) | (3.3B) | (1.5B) |
| Non-Operating | |||||
| Interest Income | 789.2M | 889.4M | 1.3B | 2.9B | 1.7B |
| Interest Expense | 136.9M | 89.9M | 23.4M | 2.9B | 3.5B |
| Net Interest Income | 652.3M | 799.5M | 1.3B | (45.3M) | (1.8B) |
| Other Non-Op Income/Expense | (2.8B) | (1.4B) | 2.2B | (7.6B) | 9.8B |
| Non-Operating Income (excl Interest) | 1.7B | — | (2.3B) | 4.6B | (13.3B) |
| EBT (Pre-Tax Income) | (10.7B) | (9.3B) | (3.0B) | (10.8B) | 8.3B |
| Income Tax Expense | (63.3M) | (51.4M) | (414.7M) | (1.1B) | 2.6B |
| Bottom Line | |||||
| Net Income | (10.6B) | (9.3B) | (2.6B) | (9.7B) | 5.7B |
| Earnings from Cont. Ops | (10.6B) | (9.3B) | (2.6B) | (9.7B) | 5.7B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.6B) | (9.3B) | (2.6B) | (9.7B) | 5.7B |
| Per Share | |||||
| Basic EPS | (₩328) | (₩271) | (₩79) | (₩292) | ₩168 |
| Diluted EPS | (₩328) | (₩271) | (₩79) | (₩292) | ₩159 |
| Revenue Per Share | ₩232 | ₩168 | ₩195 | ₩289 | ₩413 |
| Shares | |||||
| Basic Shares Outstanding | 31.2M | 34.2M | 32.9M | 33.2M | 33.9M |
| Diluted Shares Outstanding | 31.2M | 34.2M | 32.9M | 33.2M | 36.0M |
| Profitability Metrics | |||||
| EBITDA | (8.7B) | (6.0B) | (956.9M) | (6.2B) | 13.2B |
| D&A | 1.8B | 1.9B | 2.0B | 1.9B | 1.6B |
| EBIT | (10.5B) | (7.9B) | (3.0B) | (8.1B) | 11.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026